Academic Journal
Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
| Τίτλος: | Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. |
|---|---|
| Συγγραφείς: | Perciani, CT, Jaoko, W, Walmsley, S, Farah, B, Mahmud, SM, Ostrowski, M, Anzala, O, Team, K, MacDonald, KS |
| Στοιχεία εκδότη: | University of Nairobi |
| Έτος έκδοσης: | 2017 |
| Συλλογή: | University of Nairobi Digital Repository |
| Θεματικοί όροι: | HIV vaccine, herpes zoster, herpesviridae infections, immune activation, mucosal immunity, varicella-zoster virus, virus diseases |
| Περιγραφή: | INTRODUCTION: A protective HIV vaccine would be expected to induce durable effector immune responses at the mucosa, restricting HIV infection at its portal of entry. We hypothesise that use of varicella-zoster virus (VZV) as an HIV delivery vector could generate sustained and robust tissue-based immunity against HIV antigens to provide long-term protection against HIV. Given that HIV uniquely targets immune-activated T cells, the development of human vaccines against HIV must also involve a specific examination of the safety of the vector. Thus, we aim to evaluate the effects of VZV vaccination on the recipients' immune activation state, and on VZV-specific circulating humoral and cellular responses in addition to those at the cervical and rectal mucosa. METHODS AND ANALYSIS: This open-label, randomised, longitudinal crossover study includes healthy Kenyan VZV-seropositive women at low risk for HIV infection. Participants receive a single dose of a commercial live-attenuated VZVOka vaccine at either week 0 (n=22) or at week 12 (n=22) of the study and are followed for 48 and 36 weeks postvaccination, respectively. The primary outcome is the change on cervical CD4+ T-cell immune activation measured by the coexpression of CD38 and HLA-DR 12 weeks postvaccination compared with the baseline (prevaccination). Secondary analyses include postvaccination changes in VZV-specific mucosal and systemic humoral and cellular immune responses, changes in cytokine and chemokine measures, study acceptability and feasibility of mucosal sampling and a longitudinal assessment of the bacterial community composition of the mucosa. ETHICS AND DISSEMINATION: The study has ethical approval from Kenyatta National Hospital/University of Nairobi Ethics and Research Committee, the University of Toronto Research Ethics Board and by Kenyan Pharmacy and Poisons Board. Results will be presented at conferences, disseminated to participants and stakeholders as well as published in peer-reviewed journals. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | English |
| Relation: | https://www.ncbi.nlm.nih.gov/pubmed/28939581; https://hdl.handle.net/11295/102067 |
| Διαθεσιμότητα: | https://hdl.handle.net/11295/102067 https://www.ncbi.nlm.nih.gov/pubmed/28939581 |
| Rights: | Attribution-NonCommercial-NoDerivs 3.0 United States ; http://creativecommons.org/licenses/by-nc-nd/3.0/us/ |
| Αριθμός Καταχώρησης: | edsbas.ECDA0654 |
| Βάση Δεδομένων: | BASE |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://hdl.handle.net/11295/102067# Name: EDS - BASE (ns324271) Category: fullText Text: View record from BASE |
|---|---|
| Header | DbId: edsbas DbLabel: BASE An: edsbas.ECDA0654 RelevancyScore: 865 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 864.807434082031 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Perciani%2C+CT%22">Perciani, CT</searchLink><br /><searchLink fieldCode="AR" term="%22Jaoko%2C+W%22">Jaoko, W</searchLink><br /><searchLink fieldCode="AR" term="%22Walmsley%2C+S%22">Walmsley, S</searchLink><br /><searchLink fieldCode="AR" term="%22Farah%2C+B%22">Farah, B</searchLink><br /><searchLink fieldCode="AR" term="%22Mahmud%2C+SM%22">Mahmud, SM</searchLink><br /><searchLink fieldCode="AR" term="%22Ostrowski%2C+M%22">Ostrowski, M</searchLink><br /><searchLink fieldCode="AR" term="%22Anzala%2C+O%22">Anzala, O</searchLink><br /><searchLink fieldCode="AR" term="%22Team%2C+K%22">Team, K</searchLink><br /><searchLink fieldCode="AR" term="%22MacDonald%2C+KS%22">MacDonald, KS</searchLink> – Name: Publisher Label: Publisher Information Group: PubInfo Data: University of Nairobi – Name: DatePubCY Label: Publication Year Group: Date Data: 2017 – Name: Subset Label: Collection Group: HoldingsInfo Data: University of Nairobi Digital Repository – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22HIV+vaccine%22">HIV vaccine</searchLink><br /><searchLink fieldCode="DE" term="%22herpes+zoster%22">herpes zoster</searchLink><br /><searchLink fieldCode="DE" term="%22herpesviridae+infections%22">herpesviridae infections</searchLink><br /><searchLink fieldCode="DE" term="%22immune+activation%22">immune activation</searchLink><br /><searchLink fieldCode="DE" term="%22mucosal+immunity%22">mucosal immunity</searchLink><br /><searchLink fieldCode="DE" term="%22varicella-zoster+virus%22">varicella-zoster virus</searchLink><br /><searchLink fieldCode="DE" term="%22virus+diseases%22">virus diseases</searchLink> – Name: Abstract Label: Description Group: Ab Data: INTRODUCTION: A protective HIV vaccine would be expected to induce durable effector immune responses at the mucosa, restricting HIV infection at its portal of entry. We hypothesise that use of varicella-zoster virus (VZV) as an HIV delivery vector could generate sustained and robust tissue-based immunity against HIV antigens to provide long-term protection against HIV. Given that HIV uniquely targets immune-activated T cells, the development of human vaccines against HIV must also involve a specific examination of the safety of the vector. Thus, we aim to evaluate the effects of VZV vaccination on the recipients' immune activation state, and on VZV-specific circulating humoral and cellular responses in addition to those at the cervical and rectal mucosa. METHODS AND ANALYSIS: This open-label, randomised, longitudinal crossover study includes healthy Kenyan VZV-seropositive women at low risk for HIV infection. Participants receive a single dose of a commercial live-attenuated VZVOka vaccine at either week 0 (n=22) or at week 12 (n=22) of the study and are followed for 48 and 36 weeks postvaccination, respectively. The primary outcome is the change on cervical CD4+ T-cell immune activation measured by the coexpression of CD38 and HLA-DR 12 weeks postvaccination compared with the baseline (prevaccination). Secondary analyses include postvaccination changes in VZV-specific mucosal and systemic humoral and cellular immune responses, changes in cytokine and chemokine measures, study acceptability and feasibility of mucosal sampling and a longitudinal assessment of the bacterial community composition of the mucosa. ETHICS AND DISSEMINATION: The study has ethical approval from Kenyatta National Hospital/University of Nairobi Ethics and Research Committee, the University of Toronto Research Ethics Board and by Kenyan Pharmacy and Poisons Board. Results will be presented at conferences, disseminated to participants and stakeholders as well as published in peer-reviewed journals. – Name: TypeDocument Label: Document Type Group: TypDoc Data: article in journal/newspaper – Name: Format Label: File Description Group: SrcInfo Data: application/pdf – Name: Language Label: Language Group: Lang Data: English – Name: NoteTitleSource Label: Relation Group: SrcInfo Data: https://www.ncbi.nlm.nih.gov/pubmed/28939581; https://hdl.handle.net/11295/102067 – Name: URL Label: Availability Group: URL Data: https://hdl.handle.net/11295/102067<br />https://www.ncbi.nlm.nih.gov/pubmed/28939581 – Name: Copyright Label: Rights Group: Cpyrght Data: Attribution-NonCommercial-NoDerivs 3.0 United States ; http://creativecommons.org/licenses/by-nc-nd/3.0/us/ – Name: AN Label: Accession Number Group: ID Data: edsbas.ECDA0654 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.ECDA0654 |
| RecordInfo | BibRecord: BibEntity: Languages: – Text: English Subjects: – SubjectFull: HIV vaccine Type: general – SubjectFull: herpes zoster Type: general – SubjectFull: herpesviridae infections Type: general – SubjectFull: immune activation Type: general – SubjectFull: mucosal immunity Type: general – SubjectFull: varicella-zoster virus Type: general – SubjectFull: virus diseases Type: general Titles: – TitleFull: Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Perciani, CT – PersonEntity: Name: NameFull: Jaoko, W – PersonEntity: Name: NameFull: Walmsley, S – PersonEntity: Name: NameFull: Farah, B – PersonEntity: Name: NameFull: Mahmud, SM – PersonEntity: Name: NameFull: Ostrowski, M – PersonEntity: Name: NameFull: Anzala, O – PersonEntity: Name: NameFull: Team, K – PersonEntity: Name: NameFull: MacDonald, KS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Type: published Y: 2017 Identifiers: – Type: issn-locals Value: edsbas – Type: issn-locals Value: edsbas.oa |
| ResultId | 1 |